Meeting NewsVideo

VIDEO: More data needed on adding monoclonal antibodies to Bruton tyrosine kinase inhibitors in CLL

December 20, 2019
ORLANDO — In this video at ASH Annual Meeting and Exposition, Ryan W. Jacobs, MD, discusses the implications of the ELEVATE-TN trial, which…
Meeting News

Novel chemotherapy-free regimen shows promise in relapsed, refractory CLL

December 19, 2019
ORLANDO — A chemotherapy-free, triplet combination regimen of umbralisib, ublituximab and venetoclax was well-tolerated and achieved high rates…
Video

VIDEO: Blinatumomab demonstrates ‘remarkable’ results for pediatric B-cell ALL

December 17, 2019
ORLANDO — In this video, Thomas Alexander, MD, pediatric oncologist and hematologist at the University of North Carolina, discusses a late…
Meeting NewsVideo

VIDEO: Debulking strategy may eliminate hospitalizations among CLL patients initiating venetoclax

December 17, 2019
ORLANDO — A debulking strategy using obinutuzumab with or without bendamustine could allow more patients with chronic lymphocytic leukemia to…
Meeting News

Chemoimmunotherapy regimen effective in CLL patients with IGHV mutations

December 12, 2019
ORLANDO — A chemoimmunotherapy regimen containing ibrutinib, fludarabine, cyclophosphamide and obinutuzumab resulted in high rates of clinical…
Meeting NewsVideo

VIDEO: First-line venetoclax-ibrutinib ‘a win on all fronts’ in CLL

December 10, 2019
ORLANDO — An all-oral combination of venetoclax plus ibrutinib in the frontline setting was well tolerated and associated with high rates of…
Meeting NewsVideo

VIDEO: Blinatumomab has potential to become ‘new standard of care’ as post-reinduction therapy for pediatric B-ALL

December 10, 2019
ORLANDO — In this video, Ryan D. Cassaday, MD, attending physician at the Seattle Cancer Care Alliance, associate professor of medicine at the…
Meeting News

Young adults endure greater toxicity, morbidity after AML treatment

December 10, 2019
ORLANDO – Adolescents and young adults treated for acute myeloid leukemia in U.S. children’s hospitals showed higher rates of toxicity…
Meeting NewsVideo

VIDEO: Venetoclax-rituximab sustains survival benefits in relapsed, refractory CLL at 4 years

December 10, 2019
ORLANDO — Venetoclax plus rituximab maintained significant improvements in PFS and OS compared with bendamustine plus rituximab 2 years…
Meeting News

Guest commentary: Most anticipated studies on chronic lymphocytic leukemia at ASH

December 2, 2019
In this Guest Commentary, Ryan W. Jacobs, MD, principal investigator of clinical trials for chronic lymphocytic leukemia at Atrium…